. 2022 Jan 1;12(1):434–458. doi: 10.7150/thno.67300

Table 1.

Summary of emerging tumor hypoxia-reversed nanomedicines for PDT-driven cancer immunotherapy. (↑= upregulation, ↓= downregulation).

Formulations	Therapeutic agents	Immunologic modulation	Ref
AuNC@MnO₂ NPs	AuNCs, MnO₂	TAAs, mDC, CD4⁺, CD8⁺, NK↑	41
Mn@CaCO₃/ICG@siRNA NPs	ICG, MnO₂, siRNA	TAAs, mDC, IL12, IL18, CD4⁺, CD8⁺, INF-γ ↑ PD-L1 ↓	42
Phototherapy hydrogel	Ce6, CAT	TAAs, mDC, CD4⁺, CD8⁺↑ HIF-1α, VEGF↓	52
R837-loaded PLGA NPs	Ce6, CAT, α-CTLA4	TAAs, mDC, CD4+, CD8+↑CTLA-4↓	54
HSA/Hb NPs	Ce6	TAAs, mDC, CD4⁺, CD8⁺, NK↑	43
ICG modified gold nanospheres	ICG,	TAAs, mDC, CD4⁺, CD8⁺↑	57
Fluorinated polymer NPS	Ce6, NLG919	TAAs, mDC, CD4⁺, CD8⁺, Trp↑ Kyn↓	44
DEX-HAase NPs	Ce6, HAase, α-PD-L1	TAAs, mDC, CTLs, INF-γ, M1 macrophage↑ M2, PD-L1 ↓	45
HPR@CCP NPs	Ce6, HAase, Cas9-Ptpn2 plasmids	TAAs, mDC, CD⁺8, INF-γ, TNF-α↑	62
PM-IR780-Met NPs	IR780, Met	TAAs, mDC, CTLs↑ Tregs, MDSC↓	46
IR775@Met@Liposomes	IR775, Met	TAAs, mDC, CTLs, INF-γ↑, PD-L1↓	63